Logo image of B8FK.DE

BIOFRONTERA AG (B8FK.DE) Stock Fundamental Analysis

FRA:B8FK - Deutsche Boerse Ag - DE000A4BGGM7 - Common Stock - Currency: EUR

2.42  +0.06 (+2.54%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to B8FK. B8FK was compared to 51 industry peers in the Pharmaceuticals industry. B8FK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. B8FK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

B8FK had positive earnings in the past year.
In the past year B8FK has reported a negative cash flow from operations.
B8FK had negative earnings in 4 of the past 5 years.
In the past 5 years B8FK reported 4 times negative operating cash flow.
B8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFB8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

B8FK has a Return On Assets of -10.62%. This is in the lower half of the industry: B8FK underperforms 70.59% of its industry peers.
B8FK's Return On Equity of -14.38% is on the low side compared to the rest of the industry. B8FK is outperformed by 68.63% of its industry peers.
Industry RankSector Rank
ROA -10.62%
ROE -14.38%
ROIC N/A
ROA(3y)-28.73%
ROA(5y)N/A
ROE(3y)-50.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
B8FK.DE Yearly ROA, ROE, ROICB8FK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 50 -50 -100 -150 -200

1.3 Margins

B8FK has a Gross Margin of 75.61%. This is in the better half of the industry: B8FK outperforms 70.59% of its industry peers.
B8FK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
B8FK.DE Yearly Profit, Operating, Gross MarginsB8FK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 100 -100

More info and screens

4

2. Health

2.1 Basic Checks

B8FK does not have a ROIC to compare to the WACC, probably because it is not profitable.
B8FK has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for B8FK has been reduced compared to a year ago.
B8FK.DE Yearly Shares OutstandingB8FK.DE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 1M 2M 3M 4M 5M
B8FK.DE Yearly Total Debt VS Total AssetsB8FK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -4.97, we must say that B8FK is in the distress zone and has some risk of bankruptcy.
B8FK has a worse Altman-Z score (-4.97) than 72.55% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that B8FK is not too dependend on debt financing.
B8FK has a better Debt to Equity ratio (0.03) than 84.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -4.97
ROIC/WACCN/A
WACC6.84%
B8FK.DE Yearly LT Debt VS Equity VS FCFB8FK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 2.19 indicates that B8FK has no problem at all paying its short term obligations.
B8FK has a Current ratio of 2.19. This is in the better half of the industry: B8FK outperforms 74.51% of its industry peers.
A Quick Ratio of 1.45 indicates that B8FK should not have too much problems paying its short term obligations.
The Quick ratio of B8FK (1.45) is better than 76.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.45
B8FK.DE Yearly Current Assets VS Current LiabilitesB8FK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.25% over the past year.
Looking at the last year, B8FK shows a very strong growth in Revenue. The Revenue has grown by 25.30%.
EPS 1Y (TTM)99.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.41%
Revenue 1Y (TTM)25.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-49.85%

3.2 Future

Based on estimates for the next years, B8FK will show a very strong growth in Earnings Per Share. The EPS will grow by 46.56% on average per year.
B8FK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.38% yearly.
EPS Next Y-4.34%
EPS Next 2Y46.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.58%
Revenue Next 2Y22.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

B8FK.DE Yearly Revenue VS EstimatesB8FK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
B8FK.DE Yearly EPS VS EstimatesB8FK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 48.40, B8FK can be considered very expensive at the moment.
Based on the Price/Earnings ratio, B8FK is valued a bit more expensive than the industry average as 60.78% of the companies are valued more cheaply.
B8FK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.22.
With a Price/Forward Earnings ratio of 22.09, B8FK is valued on the expensive side.
B8FK's Price/Forward Earnings is on the same level as the industry average.
B8FK's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.86.
Industry RankSector Rank
PE 48.4
Fwd PE 22.09
B8FK.DE Price Earnings VS Forward Price EarningsB8FK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
B8FK.DE Per share dataB8FK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

B8FK's earnings are expected to grow with 46.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.56%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

B8FK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA AG

FRA:B8FK (5/2/2025, 7:00:00 PM)

2.42

+0.06 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-26 2024-11-26
Earnings (Next)04-30 2025-04-30/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap14.71M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 48.4
Fwd PE 22.09
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)0.05
EY2.07%
EPS(NY)0.11
Fwd EY4.53%
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS3.56
BVpS2.94
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.62%
ROE -14.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.61%
FCFM N/A
ROA(3y)-28.73%
ROA(5y)N/A
ROE(3y)-50.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.47%
Cap/Sales 2.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.45
Altman-Z -4.97
F-ScoreN/A
WACC6.84%
ROIC/WACCN/A
Cap/Depr(3y)88.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.94%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.41%
EPS Next Y-4.34%
EPS Next 2Y46.56%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)25.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-49.85%
Revenue Next Year22.58%
Revenue Next 2Y22.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y238.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.09%
OCF growth 3YN/A
OCF growth 5YN/A